The United States Food and Drug Administration approved Bayer’s Lampit (nifurtimox) for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi.
If you are not happy with the results below please do another search
50 search results for: drugs in development
In professional sports it is rare for a new franchise to win a championship right away. Not so much these days in pharma. Four members of the launch class of 2018 led their entire categories in sales by the following year
As large pharmaceutical companies increasingly look to outsource aspects of drug discovery and development to external collaborators, the ability to identify the right partnership candidates before competitors has become critical.
The healthcare industry is increasingly focusing on niche patient populations. However, finding hard-to-reach rare disease patients is difficult and keeping them engaged over time even more so. Could machine learning platforms that deliver personalized experiences for patients and caregivers be part of the answer?
Naming a column the “Cutting Edge” in these times may seem presumptuous. Not too long ago, “cutting edge” meant the cusp of innovation, the tech pathway to fantastic discoveries and business success. Who wouldn’t want to be out there? Today, the cutting edge we’re facing is like something out of a horror film – a whirling relentless blade that’s lopping off established institutions with relentless energy and unprecedented speed. Workplace? What’s that? Workforce? Who are they? Economy? Who knows?
The confusion and infighting that has marred the response to the COVID-19 pandemic reduces public support for and confidence in preventive measures encouraged by public health experts. It also threatens the effectiveness, scientific integrity, and reputation of key federal health agencies, potentially inflicting long-lasting damage.
REALITYRx added life sciences veteran Steve Nothel to the agency’s senior management ranks. Nothel joined REALITYRx as senior VP, business development.
Akcea Therapeutics Inc., a majority-owned affiliate of Ionis Pharmaceuticals Inc., made William Andrews, M.D., FACP, chief medical officer, effective immediately. Tracy Palmer Berns has joined the company as chief compliance officer, and Dr. Kia Motesharei is now senior VP, business development and corporate strategy.
Laurent Fischer, M.D., joined Adverum Biotechnologies Inc. as CEO and a member of the board of directors. Leone Patterson, who served for four years in executive leadership roles at Adverum – most recently as CEO – continues to serve as the company’s president.
The U.S. Food and Drug Administration approved ViiV Healthcare’s Dovato (dolutegravir/lamivudine) as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed on a stable ARV regimen with no history of treatment failure and no known resistance to the individual components of Dovato.